Compounders Research Compare

Crescent Biopharma, Inc.(CBIO)

Biotechnology · Waltham, MA

$13.81-0.13 (-0.95%)

Delayed quote: Oct 6, 2026, 12:40 PM EDT

About Crescent Biopharma, Inc.

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Waltham, MA

44 employees

crescentbiopharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Joshua T. Brumm

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T16:41:34.121Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:41:34.121Z.

Quote observation: 2026-10-06T16:40:22.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 512,879,809
Total debt · period ending 2026-06-30: 1,437,000
Cash · period ending 2026-06-30: 171,593,000
TTM free cash flow · period ending 2026-06-30: -153,618,000

FMP input reference: efaaa36d31f915a5dffaa91b800fc30e2d7f64892a7236e7a1e7b68ff3f7d584

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CBIO EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

CBIO Competitors' EV/FCF Ratio

Crescent Biopharma, Inc.

Current

Market Cap

$512.88M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

908 Devices Inc.

Market Cap

$509.56M

EV/FCF Ratio

935.35x

TTM Avg

716.21x

3Y Avg

716.21x

5Y Avg

716.21x

Altimmune, Inc.

Market Cap

$518.27M

EV/FCF Ratio

N/A

TTM Avg

0.12x

3Y Avg

0.12x

5Y Avg

0.12x

Allogene Therapeutics, Inc.

Market Cap

$507.38M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Monopar Therapeutics Inc.

Market Cap

$522.73M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Oculis Holding AG

Market Cap

$496.23M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Immix Biopharma, Inc.

Market Cap

$527.70M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Evolus, Inc.

Market Cap

$493.91M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ProKidney Corp.

Market Cap

$534.64M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Delcath Systems, Inc.

Market Cap

$538.61M

EV/FCF Ratio

28.19x

TTM Avg

31.80x

3Y Avg

42.09x

5Y Avg

42.09x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Crescent Biopharma, Inc. (CBIO)	$512.88M	N/A	N/A	N/A	N/A
908 Devices Inc. (MASS)vs ›	$509.56M	935.35x	716.21x	716.21x	716.21x
Altimmune, Inc. (ALT)vs ›	$518.27M	N/A	0.12x	0.12x	0.12x
Allogene Therapeutics, Inc. (ALLO)vs ›	$507.38M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$522.73M	N/A	N/A	N/A	N/A
Oculis Holding AG (OCS)vs ›	$496.23M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$527.70M	N/A	N/A	N/A	N/A
Evolus, Inc. (EOLS)vs ›	$493.91M	N/A	N/A	N/A	N/A
ProKidney Corp. (PROK)vs ›	$534.64M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$538.61M	28.19x	31.80x	42.09x	42.09x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics